Zaina P. Qureshi

Dr. Zaina P. Qureshi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
DHDoris K Hansen
Doris K Hansen
XLXiaoxiao Lu
Xiaoxiao Lu
OPOmar Castaneda Puglianini
Omar Castaneda Puglianini
SSSonja Sorensen
Sonja Sorensen
SUSaad Z. Usmani
Saad Z. Usmani
SJSundar Jagannath
Sundar Jagannath
Introduction: Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM). In the phase 3 trial, CARTITUDE-4 (NCT04181827), cilta-cel demonstrated improved efficacy vs. standard of care (SOC; daratumumab plus pomalidomide and dexamethasone [DPd] or pomalidomide plus bortezomib and dexamethasone [PVd]) with a ≥ complete response (≥CR) rate of 73.1% vs. 21.8%.Methods: A cost-per-responder model was developed to assess the value of cilta-cel and SOC (87% DPd and 13% PVd) based on the CARTITUDE-4 trial data from a US mixed payer perspective (76.7% commercial, 23.3% Medicare). The model was developed using progression-free survival (PFS), overall survival (OS), and ≥CR endpoints from CARTITUDE-4 over a period of 25.4 months. Inpatient stays, outpatient visits, drug acquisition, administration, and monitoring costs were included. The base-case model assumed an inpatient setting for each cilta-cel infusion; another scenario included 30% outpatient and 70% inpatient infusions. Costs of managing grade 3-4 adverse events (AEs) and grade 1-4 cytokine release syndrome and neurotoxicity were included. Subsequent therapy costs were incurred after disease progression; terminal care costs were considered upon death events. Outcomes included total cost per treated patient, total cost per complete responder, and cost per month in PFS between cilta-cel and SOC. Costs were adjusted to 2024 US dollars.Results: Total cost per treated patient, total cost per complete responder, and total cost per month in PFS were estimated at $704,641, $963,941, and $30,978 for cilta-cel, respectively, and $840,730, $3,856,559, and $42,520 for SOC over the 25.4-month period. Cost drivers included treatment acquisition costs before progression and subsequent treatment costs ($451,318 and $111,637 for cilta-cel; $529,795 and $265,167 for SOC). A scenario analysis in which 30% of patients received an outpatient infusion (assuming the same payer mix) showed a lower cost per complete responder for cilta-cel ($956,523) than those with an infusion in the inpatient setting exclusively.Discussion: This analysis estimated that cost per treated patient, cost per complete responder, and cost per month in PFS for cilta-cel were remarkably lower than for DPd or PVd, highlighting the substantial clinical and economic benefit of cilta-cel for patients with RRMM.

18 April 2026 in Oncology and Therapy
Verified
Journal Article
Open access
PDF file
SSSurbhi Sidana
Surbhi Sidana
SNSaurabh P. Nagar
Saurabh P. Nagar
SGSabyasachi Ghosh
Sabyasachi Ghosh
LFLin Fan
Lin Fan
VAVictoria Alegria
Victoria Alegria
RFRafael Fonseca
Rafael Fonseca
Introduction Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved in the USA for relapsed or refractory multiple myeloma (RRMM) as early as following first relapse, based on pivotal CARTITUDE-1 (≥ 4 prior lines of therapy [LOT]) and CARTITUDE-4 (1–3 prior LOT) trials, which reported high response rates and prolonged survival. In CARTITUDE-1 and CARTITUDE-4, rates of all-grade parkinsonism were 6% and < 1%, respectively, while rates of cranial nerve palsy were 3% and 9%, respectively. This study aimed to characterize new-onset nonimmune effector cell-associated neurotoxicity syndrome (non-ICANS) neurologic events (NEs) among patients with RRMM receiving cilta-cel after 1–3 or ≥ 4 prior LOT. Methods This retrospective study used two real-world data sources: open and closed insurance claims from the Komodo Research Database (February 2021–November 2024), and electronic medical records from Loopback Analytics (February 2021–December 2024). New-onset non-ICANS NEs, including parkinsonism, cranial nerve palsy, and Guillain–Barré syndrome, were assessed from cilta-cel infusion until the end of clinical activity, death, or end of data availability. Analyses were conducted separately by database and stratified by LOT. Results In patients with 1–3 prior LOT (Komodo: 124; Loopback: 79), over a median follow-up of 3.4–3.5 months, cranial nerve palsy occurred in 5.6% and 5.1% in Komodo and Loopback, respectively, with no parkinsonism or Guillain–Barré syndrome observed. In patients with ≥ 4 prior LOT (Komodo: 524; Loopback: 191), over a median follow-up of 13.2–13.3 months, parkinsonism occurred in 1.0% in both databases, cranial nerve palsy in 4.6% and 1.0%, and Guillain–Barré syndrome in 0.2% and 0.5% in Komodo and Loopback, respectively. Conclusions In this real-world study, rates of non-ICANS NEs post-cilta-cel infusion across two databases were comparable to or lower than prior trials or real-world studies, reinforcing the favorable risk–benefit profile of cilta-cel in routine practice. Graphical Abstract available for this article. Graphical Abstract The alternative text for this image may have been generated using AI.

12 May 2025 in Blood Advances
Verified
Journal Article
Open access
JAJohn Allan
John Allan
TRTao Ran
Tao Ran
ZDZhijie Ding
Zhijie Ding
JHJinghua He
Jinghua He
ABAlex Bokun
Alex Bokun
SOSusan M. O'BRien
Susan M. O'BRien
In patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), high-risk cytogenetic features such as del(17p), del(11q), and unmutated immunoglobulin variable heavy chain (IGHV) may be associated with unfavorable outcomes. In this large retrospective cohort study, data from a nationwide electronic health record-derived deidentified database were analyzed to assess real-world overall survival (rwOS) among patients treated with first-line (IL) ibrutinib with and without high-risk cytogenetic features (i.e., del(17p), del(11q), unmutated IGHV). Inverse probability of treatment weighting was used to account for differences in patient characteristics between cohorts. Of the 1,242 patients included, 969 and 273 had high- and non-high-risk CLL/SLL, with a mean age of 70.0 and 70.8 years, and a median follow up of 32 and 31 months, respectively. Within the high-risk cohort, 32.9%, 36.7%, and 58.7% had the presence of del(17p), del(11q), and unmutated IGHV, respectively. Median rwOS was not reached for either cohort; the hazard ratio (HR; 95% confidence interval [CI]) comparing rwOS between the two cohorts was 1.09 (0.79, 1.51). In a sensitivity analysis where del(11q) was not part of the high-risk definition, similar results were found, with a HR (95% CI) of 1.19 (0.86, 1.64) and median rwOS not reached for either cohort. Similarly, among the subgroup of patients with Medicare coverage, the HR (95% CI) was 0.98 (0.63, 1.53), and median rwOS was not reached. In this real-world study using a large community healthcare dataset, there was no difference in rwOS between patients treated with 1L ibrutinib with and without high-risk cytogenetic features.

24 March 2026 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
SASikander Ailawadhi
Sikander Ailawadhi
DHDoris K. Hansen
Doris K. Hansen
BDBinod Dhakal
Binod Dhakal
LSLeyla O. Shune
Leyla O. Shune
LALarry D. Anderson
Larry D. Anderson
DSDouglas W. Sborov
Douglas W. Sborov
Introduction Ciltacabtagene autoleucel (cilta-cel) was approved in February 2022 for adults with relapsed/refractory multiple myeloma (RRMM). This study evaluated US real-world outcomes among patients with RRMM treated with cilta-cel after ≥ 4 prior lines of therapy (4 + pLOT), overall and stratified by receipt of bridging therapy (BT). Methods Adults with RRMM receiving standard-of-care cilta-cel after 4 + pLOT were identified using claims data from the Komodo Research Database (01/01/2016–06/30/2024). Treatment-free interval (TFI; time between cilta-cel infusion and initiation of next treatment or death) and overall survival (OS) were evaluated using Kaplan–Meier (KM) analyses. Adjusted multivariate Cox regression was used to assess hazard ratios (HR) and 95% confidence intervals (CIs) for TFI/OS by receipt of BT. Results Among 242 patients receiving cilta-cel (mean age 63.4 years, 45.5% were female patients, 54.5% were male patients), those with BT (75.2%) had a higher comorbidity burden (mean Quan-Charlson Comorbidity Index 5.3 vs. 4.7) and higher frailty index score (mild-to-severe 49.4% vs. 28.3%) than those without. The median follow-up was 11 months. Using KM methods to account for variable follow-up, the estimated TFI at 18 months post-infusion was 80.3%, while the KM estimate of OS at 18 months post-infusion was 93.4%. Median TFI or OS was not reached. Patients with BT were numerically less likely to have a TFI event (HR 0.76, 95% CI 0.32–1.80) and more likely to remain alive (HR 0.48, 95% CI 0.13–1.70) relative to those without BT. Conclusion Consistent with pivotal trials, cilta-cel was effective in patients with RRMM and 4 + pLOT in US clinical practice. Findings align with previous results supporting BT effectiveness. Graphical abstract available for this article. Graphical Abstract

26 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TGTara K Gregory
Tara K Gregory
KBKevin C. De Braganca
Kevin C. De Braganca
VAVictoria Alegria
Victoria Alegria
MPMatthew Perciavalle
Matthew Perciavalle
RPRavi Potluri
Ravi Potluri
ZQZaina P. Qureshi
Zaina P. Qureshi
Background/Objectives: Ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma is typically administered inpatient (IP) to monitor for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Because cilta-cel toxicities are typically delayed, outpatient (OP) administration (infusion and early monitoring) is being explored. We synthesized available evidence on OP and IP administration. Methods: MEDLINE, Embase, and Cochrane Library were searched from inception to 5 August 2025, supplemented by conference and gray literature searches. Eligible studies of adults with multiple myeloma receiving cilta-cel reported efficacy, safety, resource use, costs, and/or quality-of-life outcomes; findings were synthesized descriptively due to heterogeneity. Results: Seventy-four records (56 studies) were included; 90 patients received OP cilta-cel. OP clinical evidence (primarily three real-world studies) showed high response rates (ORR: 95%; median follow-up 4.6 months) and reported 1-year PFS and OS of 86% and 96%. In IP studies, median ORR was 91%, with median 1-year PFS 76% and median 1-year OS 85%. Any-grade CRS and ICANS occurred in 79–84% and 17–22% of OP patients (largely low grade); IP cohorts reported a median ICANS incidence of 17% (range 5–23%). Most OP patients were later hospitalized (86–93%), but stays were shorter (median 4–6.5 days) than in an IP cohort (median 19 days). Comparisons were unadjusted and may reflect selection differences. One modeling-based economic analysis estimated savings of ~$19,000 per OP-treated patient. Conclusions: OP cilta-cel appears feasible for selected patients and may reduce costs without compromising outcomes. Findings are descriptive and hypothesis-generating and prospective multicenter studies are needed to define long-term safety, durability, quality of life, and cost-effectiveness.

1 February 2026 in Current Medical Research and Opinion
Verified
Journal Article
Open access
DHDoris K. Hansen
Doris K. Hansen
OPOmar Alexis Castaneda Puglianini
Omar Alexis Castaneda Puglianini
AGAriel Grajales-Cruz
Ariel Grajales-Cruz
SNSaurabh P. Nagar
Saurabh P. Nagar
SGSabyasachi Ghosh
Sabyasachi Ghosh
MJMurali Janakiram
Murali Janakiram
Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) therapy, received initial US Food and Drug Administration (FDA) approval on 02...